| May. 19, 2008 | Print This | Email This |
| |
|
|
|
Dr. Dieter Lutticken, who presented the award, with a prize fund of 20,000 Euro said: "There has been a long and intimate relationship between life sciences and statistics. Prof. Gettinby's innovative statistical and epidemiological research methods are an excellent example of refining and reducing the use of animals in sea-lice treatments in salmon farming. I am pleased that we can honor Prof. Gettinby at the World Aquaculture Conference today."
The panel of jury experts praised "Prof. Dr. Gettingby's innovating mathematical model approach for investigating the optimal use of treatments and one which involves minimal use of animals. In addition, these methods also minimize the use of veterinary medicines in the environment."
Prof. Gettinby said: "I am honored to receive the Dieter Lutticken Award and it is pleasing to know that the Award has come as a result of the increasing role of statistics and mathematical modelling in the pursuit of medicines for animals and the improved health of species in aquaculture. In accepting this award, I gratefully acknowledge the collaboration, support and work of the Marine Harvest Ltd, Scottish Quality Salmon, the UK Department for Environment, Food and Rural Affairs and the Epi-informatics research group at the
The Dieter Lutticken award, established in 2004, aims to encourage research into the use of alternative models for animal testing with significant impact on the development or production of new animal health products. Intervet/Schering-Plough Animal Health welcomes submissions from scientists and public life-science institutions. The euro 20,000 award is named after Dr. Dieter Lutticken, a committed researcher in microbiology and virology. He guided and shaped Intervet's R&D for more than a quarter of a century. Dr. Lutticken retired in 2003 from his position as Vice President and Head of R&D.
The award's scope covers in vitro models used in R&D which replace animal testing for licensing purposes as well as studies avoiding the use of animals in efficacy, safety and quality testing in the production of biologicals and pharmaceuticals for animals.
A jury panel composed of experts from public institutions of the animal health/animal testing sector and Intervet representatives looks for possible candidates and makes the final selection. Intervet also welcomes submissions from all life-science research institutions. Commercial organizations are excluded. For more information on applications, please contact Global Communications, Animal Health, Boxmeer, The Netherlands (communications@intervet.com). This year's deadline is November 15, 2008.
Note for the editor
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its website is www.schering-plough.com.
For more information about Intervet/Schering-Plough Animal Health visit the following website: www.intervet.com
Schering-PloughCONTACT: Media, Sabine Schueller, +31-485-587085, or Investor Contact,
Joseph Romanelli, +1-908-298-7436
Web site: http://www.schering-plough.com/
Company News On-Call: http://www.prnewswire.com/comp/777050.html/